this post was submitted on 01 Aug 2025
42 points (100.0% liked)

Australia

4412 readers
190 users here now

A place to discuss Australia and important Australian issues.

Before you post:

If you're posting anything related to:

If you're posting Australian News (not opinion or discussion pieces) post it to Australian News

Rules

This community is run under the rules of aussie.zone. In addition to those rules:

Banner Photo

Congratulations to @Tau@aussie.zone who had the most upvoted submission to our banner photo competition

Recommended and Related Communities

Be sure to check out and subscribe to our related communities on aussie.zone:

Plus other communities for sport and major cities.

https://aussie.zone/communities

Moderation

Since Kbin doesn't show Lemmy Moderators, I'll list them here. Also note that Kbin does not distinguish moderator comments.

Additionally, we have our instance admins: @lodion@aussie.zone and @Nath@aussie.zone

founded 2 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] Finalsolo963@lemmy.blahaj.zone 5 points 1 day ago (1 children)

What exactly is this in response to? Like the article goes over all the failings of the US healthcare system that anyone who's paying attention is well aware of, but to what end? Who was saying that Australia had anything to do with the US's healthcare system?

[–] butters@aussie.zone 7 points 1 day ago (1 children)

There’s a good explainer article here: https://www.theguardian.com/australia-news/2025/mar/22/us-pharma-trump-australia-pbs-explainer

It all came up in the tariff negotiations - the PBS in Australia means US drug companies don’t make enough money and/or US citizens are paying more for drugs than Australians.

Big pharma in the US claims Australians aren’t paying enough for medicines, considering the billions they pour into research and development, and there are too many delays in getting drug approvals.

PhRMA has asked the Trump administration to put Australia on a “watch list” and wants it to push for change, saying Australia has set the bar too high on cost effectiveness. Australia’s price reductions and “restrictive subsidy caps” meant prices were too low to support investment in innovation, it claims. There are also too many delays in approval processes, it says, adding that the PBS continues to list generic products without the patent owner’s consent.

[–] Taleya@aussie.zone 7 points 1 day ago

The official diplomatic response to US requests along these lines better be loud laughter